Showing 5451-5460 of 10175 results for "".
- Study: Lifileucel Shows Sustained Benefit in Advanced Melanoma Over 5 Yearshttps://practicaldermatology.com/news/lifileucel-shows-sustained-benefit-in-advanced-melanoma-over-5-years/2475031/Lifileucel showed sustained benefit and safety in a 5-year follow-up analysis of the phase II C-144-01 study in patients with advanced melanoma, according to a new study in the Journal of Clinical Oncology. Patien
- Probiotic for Oily and Acne-Prone Skin Gets US Patenthttps://practicaldermatology.com/news/Probiotic-Oily-Acne-Prone-Skin-Gets-US-Patent/2474976/A probiotic for managing oily, acne-prone skin was awarded US Patent No. 12,194,068, Codex Labs announced. In an independent clinical trial at Integrative Skin Solutions Research involving 18 male and female subjects with mild to moderate acne, the measured improvement after 8 weeks of Cod
- National Psoriasis Foundation Awards ZORYVE Seal of Recognitionhttps://practicaldermatology.com/news/national-psoriasis-foundation-awards-zoryve-seal-of-recognition/2474950/The National Psoriasis Foundation (NPF) awarded its first Seal of Recognition to ZORYVE® (roflumilast) cream and foam 0.3%, according to a press release from the Foundation. The NPF Seal of Recognition, according to the org
- LEO Pharma Launches Study of Delgocitinib for PPPhttps://practicaldermatology.com/news/leo-pharma-launches-study-of-delgocitinib-for-ppp/2474972/LEO Pharma announced today the initiation of a phase 2a trial looking at the safety and efficacy of delgocitinib cream in adults with palmoplantar pustulosis (PPP). According to a news release from the manufacturer, the DELTA
- Analysis: PBoNT/A and ABoNT/A Show Fastest Onset in Glabellar Line Treatmenthttps://practicaldermatology.com/news/prabotulinum-toxin-a-demonstrates-sustained-efficacy-at-day-180/2474898/A newly published study reports the comparative effects of four botulinum toxin A (BoNT/A) formulations on glabellar strain, with observed differences in onset, longevity, and muscular strain patterns. Researchers publishing
- Zasocitinib Effective in TYK2 Inhibition for Inflammatory Skin Disease: Studyhttps://practicaldermatology.com/news/zasocitinib-effecgive-in-tyk2-inhibition-for-inflammatory-skin-disease/2474891/Zasocitinib, billed as a 'next-generation' therapy, showed pharmacologic potency and high specificity compared to Janus and other kinase inhibitors, according to new results published in the Journal of Investigative Dermatology</
- Study: Most Global Melanoma Cases Attributable to UV Exposurehttps://practicaldermatology.com/news/study-most-global-melanoma-cases-attributable-to-uv-exposure/2474874/A new global analysis of cutaneous melanoma (CM) shows ultraviolet radiation (UVR) as the primary driver behind the majority of CM cases worldwide in 2022. Researchers used updated incidence estimates from GLOBOCAN 2022 (exclud
- From WHA78: Skin Diseases Are a Global Public Health Priorityhttps://practicaldermatology.com/news/wha78-skin-diseases-are-a-global-public-health-priority/2474881/In what was termed a historic decision at the 78th World Health Assembly (WHA78) in Geneva, Member States unanimously adopted a resolution declaring skin diseases a global public health priority, according to a press statement.
- HADLIMA Cleared for Substitution with Humira in All Forms: FDAhttps://practicaldermatology.com/news/hadlima-cleared-for-substitution-with-humira-in-all-forms-fda/2474836/The US Food and Drug Administration (FDA) has granted full interchangeability status to adalimumab-bwwd (HADLIMA™), a biosimilar of Humira® (adalimumab), across all forms and concentrations, according to a press release from Organon.
- EFFISAYIL 2: Spesolimab Associated with Long-Term GPP Reliefhttps://practicaldermatology.com/news/effisayil-2-spesolimab-associated-with-long-term-gpp-relief/2474835/Patients with generalized pustular psoriasis (GPP) experienced sustained symptom control and quality of life (QoL) improvements when treated with spesolimab, according to an analysis of results from the EFFISAYIL 2 trial. Re